A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer

This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Ovarian Cancer Adnexal Diseases Biomarker Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year–80 year

Sex eligibility

Female

Study type

Observational

Primary location

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with ovarian cancer.
Willingness to undergo biomarker testing.
Ability to provide informed consent for participation in the study.

Exclusion criteria

Inability to comply with study requirements or follow-up visits.
Previous participation in a conflicting clinical trial.

Treatment and study plan

Sequencing of DNA, RNA, and Proteins

Genetic

Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.

Primary outcomes

Biomarker explorarion

Time frame: 5 years

Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer.

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2028
Study completion: 2028
First posted: Jul 3, 2024
Registry last updated: Jul 3, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting